Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Rating of “Buy” from Brokerages

Monopar Therapeutics Inc. (NASDAQ:MNPR) has been assigned an average rating of “Buy” from the thirteen analysts that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, ten have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $106.20.

Several research analysts have recently issued reports on the company. Raymond James Financial downgraded Monopar Therapeutics from a “strong-buy” rating to an “outperform” rating and lowered their price objective for the company from $142.00 to $123.00 in a research note on Friday, November 14th. Chardan Capital raised their price target on shares of Monopar Therapeutics from $85.00 to $100.00 and gave the company a “buy” rating in a research note on Sunday, November 9th. Jones Trading upgraded shares of Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Friday, October 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Wednesday, October 8th. Finally, Leerink Partnrs raised Monopar Therapeutics to a “strong-buy” rating in a report on Monday, November 10th.

Monopar Therapeutics Stock Performance

NASDAQ:MNPR opened at $87.36 on Thursday. The firm’s 50-day simple moving average is $83.70 and its 200 day simple moving average is $53.94. Monopar Therapeutics has a 52 week low of $18.81 and a 52 week high of $105.00. The firm has a market cap of $583.56 million, a price-to-earnings ratio of -25.40 and a beta of 1.35.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.02). Sell-side analysts anticipate that Monopar Therapeutics will post -1.65 EPS for the current year.

Insider Activity

In related news, major shareholder Tactic Pharma Llc sold 550,229 shares of Monopar Therapeutics stock in a transaction that occurred on Wednesday, September 24th. The stock was sold at an average price of $63.61, for a total value of $35,000,066.69. Following the transaction, the insider directly owned 272,026 shares of the company’s stock, valued at $17,303,573.86. The trade was a 66.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 20.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP acquired a new stake in Monopar Therapeutics during the 3rd quarter worth about $18,904,000. Vanguard Group Inc. grew its stake in Monopar Therapeutics by 140.7% during the third quarter. Vanguard Group Inc. now owns 208,218 shares of the company’s stock worth $17,005,000 after purchasing an additional 121,729 shares during the period. Deerfield Management Company L.P. bought a new stake in Monopar Therapeutics in the third quarter worth approximately $13,048,000. TCG Crossover Management LLC acquired a new position in Monopar Therapeutics in the third quarter valued at approximately $12,496,000. Finally, ADAR1 Capital Management LLC boosted its holdings in shares of Monopar Therapeutics by 28.7% during the 3rd quarter. ADAR1 Capital Management LLC now owns 129,999 shares of the company’s stock worth $10,617,000 after buying an additional 29,025 shares in the last quarter. Institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.